Cambrex to Exhibit at InformexUSA 2011

East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, "Cambrex") will be exhibiting its small molecule API products, services and technologies designed to enhance the efficacy of finished drug products at InformexUSA 2011, February 7-10 in Charlotte, NC. In addition, Cambrex personnel will give two presentations at the Informex Showcases on February 7.

Cambrex will be showcasing its contract service capabilities ranging from development to finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, along with advanced intermediate products.

During the Informex Exhibitor Showcase, Dan Giambattisto, Vice President of Drug Delivery will present the latest developments in Cambrex’s drug delivery and final dosage formulation and manufacturing capabilities. Cambrex has proprietary platforms designed to deliver technology-enhanced APIs and novel dosage forms that accelerate the commercialization of finished drug products. In addition, Mr. Giambattisto will discuss the recent acquisition of Cambrex Zenara which has furthered Cambrex’s leadership in Nicotine Replacement Therapy products.

Dr. Antje Gupta, General Manager of Cambrex IEP, will present at the Informex Technology Showcase. Her presentation will detail Cambrex’s enzymatic enantioselective reduction and transaminase technologies, and the benefits of using this green technology for cost-effective production of chirally pure intermediates and APIs.

Cambrex is exhibiting at booth 1223 in the Charlotte Convention Center during InformexUSA. (NYSE: CBM, "Cambrex") will be exhibiting its small molecule API products, services and technologies designed to enhance the efficacy of finished drug products at InformexUSA 2011, February 7-10 in Charlotte, NC. In addition, Cambrex personnel will give two presentations at the Informex Showcases on February 7.

Cambrex will be showcasing its contract service capabilities ranging from development to finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, along with advanced intermediate products.

During the Informex Exhibitor Showcase, Dan Giambattisto, Vice President of Drug Delivery will present the latest developments in Cambrex’s drug delivery and final dosage formulation and manufacturing capabilities. Cambrex has proprietary platforms designed to deliver technology-enhanced APIs and novel dosage forms that accelerate the commercialization of finished drug products. In addition, Mr. Giambattisto will discuss the recent acquisition of Cambrex Zenara which has furthered Cambrex’s leadership in Nicotine Replacement Therapy products.

Dr. Antje Gupta, General Manager of Cambrex IEP, will present at the Informex Technology Showcase. Her presentation will detail Cambrex’s enzymatic enantioselective reduction and transaminase technologies, and the benefits of using this green technology for cost-effective production of chirally pure intermediates and APIs.

Cambrex is exhibiting at booth 1223 in the Charlotte Convention Center during InformexUSA.